The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study, initiated in 2001, was a landmark for psychiatry, one of the “big 3” effectiveness studies intended to better understand real-world clinical outcomes.1 It aimed to address the lack of head-to-head data regarding next-step treatment options in major depressive disorder, a clinical scenario that STAR*D itself demonstrated could affect up to two-thirds of individuals beginning antidepressant treatment.2
Perlis RH, Fava M. Is It Time to Try Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Again? JAMA Psychiatry. 2022;79(4):281–282. doi:10.1001/jamapsychiatry.2021.4281
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.